Faculty of Pharmacy, Applied Science University Amman, Amman, Jordan.
Diabetes Metab. 2010 Feb;36(1):43-50. doi: 10.1016/j.diabet.2009.06.009. Epub 2009 Dec 31.
The present study investigated the cyclooxygenase (COX) pathway to elucidate any changes that may be involved in the mechanism(s) underlying diabetic fetopathy.
Diabetes was induced in female rats (n=12) by two successive daily injections of 55 mg/kg streptozotocin, while control animals (n=10) were injected with a buffer solution; hyperglycaemia was confirmed by blood glucose levels greater than 11 mmol/L. The study female rats were made pregnant and, on day 15 of gestation, the rats were sacrificed, and the fetuses, placentas and membranes dissected out of the uterine horns. Following morphological examination, the fetuses, placentas and membranes were homogenized, and used to measure COX activities and prostaglandin (PG) E(2) and PGF(2alpha) levels.
Fetuses from diabetic mothers exhibited significantly (P<0.05) shorter crown-to-rump lengths, lower body weights and heavier placental weights. The activity of COX-1 in the fetuses, placentas and membranes from diabetic mothers represented a small percentage of total COX activity compared with that of COX-2. The presence of a COX-1 inhibitor in the control and diabetic rats was investigated and found to be negative. The activity of COX-2 in malformed fetuses from diabetic mothers was significantly lower (P<0.05) compared with non-malformed fetuses from control and diabetic mothers. The mean level of PGE(2) in fetuses from diabetic mothers was significantly (P<0.05) lower than that in controls. In contrast, the biggest increases in PGF(2alpha) were observed in the malformed diabetic fetuses, placentas and membranes.
The increased production of PGF(2alpha) probably proceeds, at least in part, independently of the COX pathway and via the isoprostane route. However, it is unclear whether the relatively high levels of PGF(2alpha) are causally related to, or simply coincidental with, fetal malformation.
本研究调查环氧化酶(COX)途径,以阐明糖尿病胎发病机制中可能涉及的任何变化。
通过连续两天两次给雌性大鼠注射 55mg/kg 的链脲佐菌素,诱导糖尿病(n=12),而对照动物(n=10)则注射缓冲液;通过血糖水平大于 11mmol/L 来确认高血糖。妊娠第 15 天,研究雌性大鼠受孕,处死大鼠,从子宫角中取出胎儿、胎盘和胎膜。进行形态学检查后,将胎儿、胎盘和胎膜匀浆,用于测量 COX 活性以及前列腺素(PG)E2 和 PGF2alpha 水平。
来自糖尿病母亲的胎儿表现出明显(P<0.05)更短的头臀长、更低的体重和更重的胎盘重量。与 COX-2 相比,来自糖尿病母亲的胎儿、胎盘和胎膜中 COX-1 的活性仅占总 COX 活性的一小部分。在对照和糖尿病大鼠中研究 COX-1 抑制剂的存在,发现其为阴性。来自糖尿病母亲的畸形胎儿中 COX-2 的活性明显(P<0.05)低于对照和糖尿病母亲的非畸形胎儿。来自糖尿病母亲的胎儿中 PGE2 的平均水平明显(P<0.05)低于对照。相反,在畸形的糖尿病胎儿、胎盘和胎膜中观察到 PGF2alpha 的最大增加。
PGF2alpha 的增加产量可能至少部分独立于 COX 途径,并通过异前列烷途径进行。然而,相对较高水平的 PGF2alpha 是否与胎儿畸形有因果关系,或者仅仅是巧合,尚不清楚。